1.0
Aug 20, 2012
Current employee, more than 5 years
Cambridge, MA
Recommend
CEO approval
Business Outlook
Pros
The science is interesting, the diseases being researched are in need of dedicated teams to create solutions, and the people who are left (after the acquisition by Sanofi) are really super.
Cons
That being said, those people are leaving in droves, and the new parent company is totally focused on the bottom line, not what makes sense for patients, and certainly not what makes sense for the employees. There is no recognition by Sanofi that Genzyme employees made Genzyme what it was, and the loss of talent in the past several months is staggering!